OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing best-in class treatments for patients with gastrointestinal disorders.
Employees: 11-50
Total raised: $39M
Founded date: 2015
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Takeda Ven... | takeda.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.05.2017 | Series A | $39M | New Enterp... |
Mentions in press and media 4
| Date | Title | Description |
| 25.05.2017 | Term Sheet — Thursday, May 25 | FIGHTS, CRYPTO-CORNS Investor fight: Blink Health, a New York-based prescription drug startup, is embroiled in another lawsuit. This week Michael Karsch, an early investor, sued the company and its founders for $30 million for violating sec... |
| 24.05.2017 | OrphoMed Raises $39M in Series A Financing | OrphoMed, Inc., a San Francisco, CA-based clinical stage biopharmaceutical company developing dimer therapies, closed a $39m Series A financing. The round was led by New Enterprise Associates (NEA), and co-led by existing seed investor Take... |
| 24.05.2017 | OrphoMed Secures $39M Series A | SAN FRANCISCO, CA, Clinical stage biopharmaceutical company developing first-in-class dimer therapies, today announced the completion of a $39 million Series A financing. >> Click here for more funding data on OrphoMed >> To... |
| 24.05.2017 | NEA Leads $39M Series A for OrphoMed | OrphoMed, Inc., a clinical stage biopharmaceutical company developing first-in-class dimer therapies, today announced the completion of a $39 million Series A financing. The round was led by New Enterprise Associates (NEA), and co-led by ex... |